A helicase that supercharges mitochondrial energy production drives colorectal cancer growth — in human tumour tissue, cancer cells and mice
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Researchers report that the helicase DDX49 is overproduced in human colorectal cancer tissue and drives tumour growth by stabilizing PGC-1α, the master regulator of mitochondrial biogenesis, thereby boosting mitochondrial respiration (Cell Death Discovery, November 3, 2026). The evidence combines human tissue correlations with cancer-cell and mouse experiments; DDX49 is a proposed drug target and biomarker, and no treatment was tested.
Cancer metabolism work usually asks how tumours ferment sugar. This study asks how they breathe — and finds a little-known helicase holding the throttle on the mitochondrial engine, in tissue taken from real patients as well as in cells and mice.
What is DDX49, and what does it do?
DDX49 is a DEAD-box helicase — a family of enzymes that unwind RNA and help run the cell's protein-making machinery. Multi-omics analysis flagged enhanced mitochondrial OXPHOS as a prominent metabolic feature of colorectal cancer and pointed to DDX49 as a novel regulator of it. In patient tissue, DDX49 was aberrantly upregulated, and high expression correlated with advanced clinicopathological stage and adverse prognosis.
How does it feed the mitochondria?
The chain the team mapped is direct: DDX49 in the nucleus binds and stabilizes PGC-1α, the coactivator widely regarded as the master switch of mitochondrial biogenesis. Stabilized PGC-1α upregulates TFAM — the factor that maintains and transcribes mitochondrial DNA — and subunits of the OXPHOS complexes, enhancing mitochondrial respiration. In vitro and in vivo assays showed DDX49 promotes cancer-cell proliferation, clonogenicity and tumour growth while suppressing apoptosis, and rescue assays confirmed PGC-1α is an essential downstream mediator: interrupt the PGC-1α link and the DDX49 effect goes with it.
What would have to happen before this helps a patient?
Everything downstream of a target-identification paper: a drug-like molecule that inhibits DDX49 without wrecking normal helicase biology, evidence it can be delivered to tumours, safety work, and then human trials. None of that exists yet. The nearer-term use the authors propose is prognostic — DDX49 levels as a biomarker of more aggressive disease — and even that needs validation in independent patient cohorts before any clinical role.
Frequently asked questions
Is DDX49 a new cancer drug target?
It is a proposed one. The study shows DDX49 drives colorectal cancer growth in cells and mice by boosting mitochondrial energy production through PGC-1α, and its levels track with worse prognosis in human tissue. No DDX49 inhibitor was tested, so there is no drug and no human treatment evidence yet.
Why do colorectal cancers need mitochondria?
Many tumours increase mitochondrial oxidative phosphorylation — the high-yield energy pathway — alongside sugar fermentation. In this study, enhanced OXPHOS was a prominent metabolic feature of colorectal cancer, and the DDX49–PGC-1α–TFAM axis was one mechanism sustaining it.
Were patients treated in this study?
No. The human component was analysis of tumour tissue and clinical correlations. All intervention experiments were in cancer cells and animal tumour models.
Where the evidence stands
- Established: That colorectal cancers can depend on mitochondrial OXPHOS, and that PGC-1α/TFAM drive mitochondrial biogenesis, are well-supported biology; this study's mechanistic chain was tested with rescue experiments.
- Preliminary: DDX49's role itself: one group's multi-omics, tissue-correlation, cell and mouse work. The human data are correlative — they do not show DDX49 causes worse outcomes in patients.
- Absent: Any DDX49-targeted drug or clinical intervention. None was tested.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.